 |
236 Diseases |  |
42 Trials |
|
42 Trials |  |
3908 News |  |
| «12345678910111213...4849» |
- | lapatinib / Generic mfg.
Trial completion, Trial completion date, Surgery: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma (clinicaltrials.gov) - Nov 6, 2024
P1, N=29, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Oct 2024
- ||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date, Metastases: DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] (clinicaltrials.gov) - Nov 5, 2024
P3, N=608, Active, not recruiting, Sponsor: Daiichi Sankyo
Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Oct 2024 Trial completion date: May 2025 --> Jul 2025
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Cost-Utility Analysis of Trastuzumab Deruxtecan Versus Treatment of Physician () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1527;
TPC was either capecitabine plus trastuzumab or capecitabine plus lapatinib. T-DXd appears not cost-effective compared with TPC for HER2-positive mBC patients who were refractory or resistant to trastuzumab emtansine in China.
- | Journal, PD(L)-1 Biomarker, IO biomarker: Construction of lysosome-related prognostic signature to predict the survival outcomes and selecting suitable drugs for patients with HNSCC. (Pubmed Central) - Nov 4, 2024
In addition, a KEGG function enrichment analysis revealed a potential relationship between the risk assessment model and cardiomyopathy. We constructed a prognostic signature based on lysosome-related genes and successfully predicted the survival outcome of HNSCC patients, which not only provides potential guidance for personalized treatment but also provides a new idea for precision treatment of HNSCC.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Efficacy and Safety of Pyrotinib Combined with Trastuzumab and Aromatase Inhibitor in Neoadjuvant Treatment of HER2+/HR+ Breast Cancer: A Single-Arm, Multi-Center Phase II Exploratory Study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2109;
- anvatabart opadotin (JNJ-0683) / J&J
ARX788 for patients with HER2-positive advanced breast cancer: characterization, time course, and monitoring and management of adverse event from the phase III ACE-Breast-02 study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2048;
- Piqray (alpelisib) / Novartis, Herceptin (trastuzumab) / Roche
Complete response with Alpelisib and Trastuzumab in a patient with ER/PR-negative, HER2-positive refractory metastatic breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2045;
- Nerlynx (neratinib) / Puma
Neratinib-based combination treatments for patients with HER2-positive breast cancer brain metastases (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2029;
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Case report: interstitial lung disease in a paciente with metastatic breast cancer treated with radiotherapy and trastuzumab deruxtecan (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1995;
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
The effectiveness of post-T-DXd treatments in patients with HER2-positive metastatic breast cancer: A nationwide Japanese cohort study (EN-SEMBLE) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1978;
- PRISM high-throughput screening to elucidate how tumor microenvironments modulate drug responses of breast cancer cells (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1766;
- Nerlynx (neratinib) / Puma
Resistance to neratinib in HER2+ breast cancer: Mechanistic insights and treatment approaches (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1182;
- Aidixi (disitamab vedotin) / Pfizer
A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis. (Stars at Night 1-2) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1019;
- anvatabart opadotin (JNJ-0683) / J&J, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_915;
- Inhibition of de novo fatty acid synthesis demonstrates broad synergistic effects with anti-cancer therapy, alters cellular lipid composition and induces endoplasmic reticulum stress (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_771;
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
HER 2 + metastatic breast cancer with central nervous involvement, response to Trastuzumab-Deruxtecan in a heavily treated patient: A case report (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_540;
- Annexin A6 modulates the secretion of pro-inflammatory cytokines and exosomes via membrane fusion with SNAP 23 in triple negative breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_462;
- | lapatinib / Generic mfg.
Journal: Annexin A6 modulates the secretion of pro-inflammatory cytokines and exosomes via interaction with SNAP23 in triple negative breast cancer cells. (Pubmed Central) - Nov 1, 2024
Moreover, cholesterol content in EVs was significantly higher in AnxA6-expressing cells than in AnxA6 downregulated cells and following chronic lapatinib induced upregulation of AnxA6...AnxA6 neutralizing antibodies strongly diminished the survival of AnxA6 low TNBC cells but had minimal effects on the survival of TNBC cells expressing relatively high levels of the protein. Together, these data suggest that AnxA6 facilitates the secretion of EVs and proinflammatory cytokines that may be critical for TNBC progression.
- | lapatinib / Generic mfg.
Trial completion date, Surgery: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma (clinicaltrials.gov) - Nov 1, 2024
P1, N=29, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Together, these data suggest that AnxA6 facilitates the secretion of EVs and proinflammatory cytokines that may be critical for TNBC progression. Trial completion date: Oct 2024 --> Oct 2025
- ||||||| oxaliplatin / Generic mfg., lapatinib / Generic mfg., capecitabine / Generic mfg.
Trial completion, Metastases: LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib (clinicaltrials.gov) - Oct 29, 2024
P3, N=545, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Oct 2024 --> Oct 2025 Active, not recruiting --> Completed
- | lapatinib / Generic mfg., erlotinib / Generic mfg.
Journal, IO biomarker: Design, synthesis, and biological evaluation of novel quinoline-based EGFR/HER-2 dual-target inhibitors as potential anti-tumor agents. (Pubmed Central) - Oct 22, 2024
The apoptotic potential activity of 5a was examined, and the findings demonstrated that 5a promotes apoptosis by activating caspase-3, 8, and Bax while simultaneously reducing the expression of the anti-apoptotic protein Bcl-2. The docking studies provided valuable insights into the binding interactions of compounds 3e and 5a with EGFR, effectively rationalizing the observed SAR trends.
- | lapatinib / Generic mfg.
Retrospective data, Journal, Metastases: Her2 positive metastatic breast cancer treated with low dose lapatinib in a resource-constrained setting in South India: a retrospective audit. (Pubmed Central) - Oct 21, 2024
Low-dose lapatinib is a regimen that offers an acceptable disease control rate. This strategy requires further exploration, particularly for the benefit of resource-limited areas.
- | Verzenio (abemaciclib) / Eli Lilly
Journal: Exploring drug repositioning possibilities of kinase inhibitors via molecular simulation. (Pubmed Central) - Oct 17, 2024
Further cell assays showed IC50 values of 0.2, 1.2 and 0.6??M in tumor cells. The consistent result between prediction and validation demonstrated that repositioning KIs via in silico method is feasible.
- | lapatinib / Generic mfg.
Journal: Lapatinib-induced enhancement of mitochondrial respiration in HER2-positive SK-BR-3 cells: mechanism revealed by analysis of proteomic but not transcriptomic data. (Pubmed Central) - Oct 15, 2024
However, it is consistent with the results of the resazurin test, which showed a 1.8-fold increase in SK-BR-3 cellular respiration upon exposure to lapatinib. Thus, we conclude that enhanced cellular respiration is a novel additional mechanism of action of lapatinib on HER2-positive cancer cells.
- | MK-2206 / Merck (MSD), Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion, Trial completion date, Metastases: Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies (clinicaltrials.gov) - Oct 1, 2024
P2, N=647, Completed, Sponsor: National Cancer Institute (NCI)
Thus, we conclude that enhanced cellular respiration is a novel additional mechanism of action of lapatinib on HER2-positive cancer cells. Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024
- ||| oxaliplatin / Generic mfg., lapatinib / Generic mfg., capecitabine / Generic mfg.
Trial completion date, Metastases: LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib (clinicaltrials.gov) - Sep 26, 2024
P3, N=545, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024 Trial completion date: Jan 2025 --> Oct 2024
- | lapatinib / Generic mfg.
Journal: Fibroblast growth factor 20 ameliorates cardiac hypertrophy via activation ErbB2. (Pubmed Central) - Sep 25, 2024
Lapatinib largely abrogated the anti-hypertrophic effect of FGF20, accompanied by increases in cardiomyocyte apoptosis and oxidative stress. In summary, this study reveals that FGF20 prevents cardiac hypertrophy by inhibiting apoptosis and oxidative stress via activating ErbB2 and may be a promising therapeutic strategy for cardiac hypertrophy.
- | lapatinib / Generic mfg.
Preclinical, Journal: Comparing the toxicity effects of copper oxide nanoparticles conjugated with Lapatinib on breast (MDA-MB-231) and lung (A549) cancer cell lines. (Pubmed Central) - Sep 24, 2024
Nuclear morphological alterations, including chromatin condensation and fragmentation, were observed in both cancer cell lines. This study indicates CuO@Lapatinib is a potent antiproliferative compound with more efficient inhibitory effects on lung cancer than breast cancer cells, which can be related to the higher ROS generation in the A549 cell line.
- | Kadcyla (ado-trastuzumab emtansine) / Roche
Journal: Long-Term Success With a TDM-1 Biosimilar in Recurrent HER2-Positive Breast Cancer With Multisite Metastases: A Comprehensive Case Study. (Pubmed Central) - Sep 20, 2024
A 54-year-old postmenopausal female patient with recurrent breast cancer and metastasis was treated with trastuzumab and paclitaxel (12 cycles), followed by trastuzumab maintenance therapy (71 cycles)...Oral therapy with lapatinib and letrozole was prescribed for a year to treat the breast cancer, along with the lesions and enhanced nodules observed in the patient's lungs, liver, and bones...This case report demonstrates the long-term efficacy of T-DM1 and its satisfactory safety profile. Overall, it provides valuable insights into the management of and challenges faced during the treatment of recurrent breast cancer with metastasis.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Remarkable response to Fam-trastuzumab deruxtecan-nxki (T-DXd) in metastatic Her2neu positive carcinoma breast with active brain disease- a case experience (Exhibition area) - Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1087;
She later developed brain metastasis for which stereotactic radiotherapy was given followed by multiple lines of anti Her2 agents: TDM1, Lapatinib+capecitabine with duration of response (DOR) of 15 and 9 months respectively...She is neurologically stable with an ongoing response of 17 months. This case demonstrated remarkable response to TDX-d in case of active brain metastasis creating a new ray of hope in this space.
- | lapatinib / Generic mfg., paclitaxel / Generic mfg.
Journal: Heat stress sensitizes zebrafish embryos to neurological and cardiac toxicity. (Pubmed Central) - Sep 15, 2024
Interestingly, the cardiotoxic effects of lapatinib, phenanthrene and paclitaxel were induced by heat stress. Taken together, our data indicates that motility and cardiac function of zebrafish embryos can be utilized as a model to analyze modulatory effects of compounds on heat stress.
- | lapatinib / Generic mfg., amiloride hydrochloride / Generic mfg.
Journal: Amiloride Sensitizes Prostate Cancer Cells to the Reversible Tyrosine Kinase Inhibitor Lapatinib by Modulating ERBB3 Subcellular Localization. (Pubmed Central) - Sep 11, 2024
Amiloride combined with lapatinib significantly increased apoptosis but did not affect AR transcriptional activity. Thus, our data indicate that a combination of amiloride and lapatinib could target HSPC tumors without problems associated with androgen deprivation therapy in localized PCa.
- | Kadcyla (ado-trastuzumab emtansine) / Roche
Journal, Metastases: Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients. (Pubmed Central) - Sep 6, 2024
The patients who progressed after trastuzumab-based chemotherapy and TDM-1 were included in the study...Treatment options are limited in heavily pretreated HER2-positive breast cancer patients. Despite a small number of patients, this study showed that the lapatinib plus capecitabine combination was effective and well-tolerated in heavily pretreated HER2-positive breast cancer patients after TDM-1.
- | Journal: Establishment of a trastuzumab-resistant extramammary Paget disease model: loss of PTEN as a potential mechanism. (Pubmed Central) - Sep 2, 2024
Despite a small number of patients, this study showed that the lapatinib plus capecitabine combination was effective and well-tolerated in heavily pretreated HER2-positive breast cancer patients after TDM-1. This study demonstrates an innovative TR EMPD-PDX model and introduces promising antineoplastic effects with various treatments for TR EMPD tumours.
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Review, Journal: Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment. (Pubmed Central) - Aug 31, 2024
Small molecules such as Lapatinib, Neratinib, and Pyrotinib were initially developed for treating breast cancer...This comprehensive review covers the structural characteristics of HER2, the HER family signaling pathway mechanism, recent findings regarding HER2 receptor involvement in various cancers, and diverse HER2-targeted therapies. This information provides a comprehensive understanding of HER2-targeted strategies in the evolving field of cancer treatment.
- | lapatinib / Generic mfg.
Preclinical, Journal: EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon ?-accelerated murine lupus. (Pubmed Central) - Aug 31, 2024
Type I Interferons are highlighted as important regulators of HER2/ErbB2 expression in the kidney. Further studies are required to parse the beneficial aspects of EGFR inhibition on autoimmunity from its negative effects on wound healing in lupus nephritis.
- || Tukysa (tucatinib) / Pfizer, Nerlynx (neratinib) / Puma
Review, Journal: Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy. (Pubmed Central) - Aug 31, 2024
Despite their success, challenges such as resistance mechanisms and off-target effects persist, urging continuous research for the development of next-generation HER2 TKIs. This comprehensive review serves as a valuable resource for pharmaceutical scientists, offering insights into the synthetic intricacies and clinical impact of small-molecule TKIs targeting HER2.
- | Mekinist (trametinib) / Novartis, BeiGene
Journal: Neutrophil extracellular trap related risk score exhibits crucial prognostic value in skin cutaneous melanoma, associating with distinct immune characteristics. (Pubmed Central) - Aug 21, 2024
We established a NET-related five gene signature in SKCM and found that the NET-related signature may exhibit a good predictive ability for SKCM prognosis. The NET score may not only predict the survival outcome and drug sensitivity in SKCM, but also reflect the immune conditions of SKCM patients.
- | lapatinib / Generic mfg.
Journal: PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer. (Pubmed Central) - Aug 15, 2024
The superior performance of PI3K PROTAC was also confirmed in lapatinib-resistant breast cancer xenograft tumors and patient-derived breast cancer organoids (PDOs). In conclusion, this study reveals that the novel PI3K PROTAC we synthesized could serve as an effective agent to overcome lapatinib resistance.
- | Tafinlar (dabrafenib) / Novartis, BeiGene
Journal: Telomere-related gene risk model for prognosis prediction in colorectal cancer. (Pubmed Central) - Aug 15, 2024
Finally, we validated the expression of the ten TRDEGs (ACACB, TPX2, SRPX, PPARGC1A, CD36, MMP3, NAT2, MMP10, HIGD1A, and MMP1) through quantitative real-time polymerase chain reaction (qRT-PCR) and found that compared to normal cells, the expression levels of ACACB, HIGD1A, NAT2, PPARGC1A, and TPX2 in CRC cells were elevated, whereas those of CD36, SRPX, MMP1, MMP3, and MMP10 were reduced. Overall, we constructed a telomere-related biomarker capable of predicting prognosis and treatment response in CRC individuals, offering potential guidance for drug therapy selection and prognosis prediction.
- | Nutlin-3 / EMD Serono
Journal, PARP Biomarker, Epigenetic controller: DNA methylation profiling deciphers three EMT subtypes with distinct prognoses and therapeutic vulnerabilities in breast cancer. (Pubmed Central) - Aug 12, 2024
Notably, to increase the clinical applicability of the EMT subtypes, we devised a 96-gene panel-based classifier via a machine learning framework. Our study identified three methylation-driven EMT subtypes with distinct prognoses and biological traits to capture heterogeneity in BC and provided a rationale for the use of this classification as a powerful tool for developing new strategies for clinical trials.
- || SPH5030 / Shanghai Pharma, Nerlynx (neratinib) / Puma
Review, Journal: Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy. (Pubmed Central) - Aug 10, 2024
This review discusses the latest research progress in HER2 TKIs, with a focus on the structural optimization process and structure-activity relationship analysis. In particular, this study highlights promising design strategies to address these challenges, providing insightful information and inspiration for future development in this field.
- | lapatinib / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Tocopherol-human serum albumin nanoparticles (Pubmed Central) - Aug 9, 2024
In particular, this study highlights promising design strategies to address these challenges, providing insightful information and inspiration for future development in this field. The resulting Lapa@HSA(VE) NPs were 117.2
- | lapatinib / Generic mfg., paclitaxel / Generic mfg.
Trial completion date: CALGB-40601: Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Aug 6, 2024
P3, N=305, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
The resulting Lapa@HSA(VE) NPs were 117.2 Trial completion date: Jul 2024 --> Jul 2025
- | Journal, IO biomarker: Identification of the novel markers of PPAR signalling affecting immune microenvironment and immunotherapy response of lung adenocarcinoma patients. (Pubmed Central) - Aug 5, 2024
The prognosis model based on eight PPAR-related genes has satisfactory prognosis prediction efficiency. Meanwhile, our results can provide direction for future studies in the relevant aspects.
- | hydroxychloroquine / Generic mfg., lapatinib / Generic mfg.
Journal: Targeting autophagy: a promising approach for the treatment of breast cancer brain metastases. (Pubmed Central) - Aug 5, 2024
Preclinical studies have shown that genetically or pharmacologically disrupting the autophagy pathway significantly decreases the brain metastatic burden, resulting in improved animal survival and increased sensitivity to lapatinib. These findings pave the way for the development of novel strategies targeting autophagy for breast cancer patients with brain metastatic disease.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report. (Pubmed Central) - Aug 5, 2024
The patient exhibited intracranial progression while receiving treatment with trastuzumab deruxtecan monotherapy after secondary brain radiotherapy and multiple lines of therapy with anti-HER2 agents, such as pyrotinib, lapatinib, tucatinib, and ado-trastuzumab emtansine...The present case indicates that the combination of anlotinib and trastuzumab deruxtecan may be a promising treatment option for patients with HER2+ breast cancer with brain metastasis. Nevertheless, further studies are warranted to verify the present findings.
- || Zejula (niraparib) / GSK, J&J
Review, Journal: Unlocking the Potential of Berberine: Advancing Cancer Therapy through Chemosensitization and Combination Treatments. (Pubmed Central) - Jul 31, 2024
Additionally, this review briefly covers the origin and biological activities of BBR, exploring the specific actions underlying its anticancer effects. Further, pharmacokinetic properties of BBR are also discussed, providing insight into its therapeutic potential and optimization of its use in cancer treatment.
- | lapatinib / Generic mfg.
Journal: Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting the TOLLIP-mediated autophagic degradation of CIP2A. (Pubmed Central) - Jul 31, 2024
The pro-tumorigenic effect of SFXN1 overexpression was partially prevented by lapatinib-mediated inhibition of the CIP2A/PP2A/p-AKT pathway. These findings may provide a new targeted therapy for patients with TNBC.
- | lapatinib / Generic mfg.
Journal: Synthesis, characterization and biological research of novel 2-(quinoline-4-carbonyl)hydrazide-acrylamide hybrids as potential anticancer agents on MCF-7 breast carcinoma cells by targeting EGFR-TK. (Pubmed Central) - Jul 29, 2024
Compound 6h was found to induce significant cellular cycle arrest at the G1 phase and provoke apoptosis. Besides, compound 6h triggered apoptosis via upregulating p53 and initiator caspase 9 by 7.4- and 8.7-fold, respectively, compared to DMSO controls.